<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787566</url>
  </required_header>
  <id_info>
    <org_study_id>TRG-002</org_study_id>
    <nct_id>NCT00787566</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting</brief_title>
  <official_title>A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Nippon Biomedical Laboratories, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shin Nippon Biomedical Laboratories, Ltd.</source>
  <brief_summary>
    <textblock>
      Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2
      dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with
      chemotherapy-induced nausea and vomiting (CINV) associated with the administration of highly
      emetogenic chemotherapy.

      Primary Objective: To select a dose for Phase 3 by assessing the efficacy, safety, and
      tolerability of 3 doses of TRG in patients with CINV associated with the administration of
      highly emetogenic chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Complete Control</measure>
    <time_frame>24 hours</time_frame>
    <description>Complete Control is defined as no emetic episodes, no use of rescue medications, and no more than mild nausea as defined by a categorial scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Complete Response</measure>
    <time_frame>24 hours</time_frame>
    <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Total Response</measure>
    <time_frame>24 hours</time_frame>
    <description>Total Response is defined as no nausea, no emetic episodes, and no use of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Major Control of Emesis</measure>
    <time_frame>24 hrs</time_frame>
    <description>Major Control of emesis = 2 emetic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Minor Control of Emesis</measure>
    <time_frame>24 hrs</time_frame>
    <description>Minor Control of emesis: 3-5 emetic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Failure</measure>
    <time_frame>24 hrs</time_frame>
    <description>Failure: &gt; 5 emetic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Using Rescue Medications</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Emetic Episode</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Medication</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to treatment failure is based on time to first emetic episode or time to rescue medication, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emetic Episodes</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Nausea Measured by a 4 Categorical Scale</measure>
    <time_frame>24 hours</time_frame>
    <description>4 categorical scale: none, mild (did not interfere with normal daily life), moderate (interfered with normal daily life), and severe (bedridden due to nausea/ required the patient to be bedridden)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Satisfaction With Antiemetic Therapy Measured by a VAS</measure>
    <time_frame>24 hours</time_frame>
    <description>VAS (visual analog scale) 0: not at all satisfied, 100: totally satisfied</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>0.5 mg of TRG (intranasal granisetron)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg dose, intranasal powder, single spray, administered once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg of TRG (intranasal granisetron)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg dose, intranasal powder, songle spray, administered once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg of TRG (intranasal granisetron)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg dose, intranasal powder, single spray, administered once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal granisetron</intervention_name>
    <description>0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen</description>
    <arm_group_label>0.5 mg of TRG (intranasal granisetron)</arm_group_label>
    <arm_group_label>1.0 mg of TRG (intranasal granisetron)</arm_group_label>
    <arm_group_label>2.0 mg of TRG (intranasal granisetron)</arm_group_label>
    <other_name>TRG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically and/or cytologically confirmed cancer

          -  ECOG performance status of 0, 1, or 2

          -  Patients with life expectancy of at least 3 months

          -  Patients who are chemotherapy na√Øve

          -  Patients who will be receiving the first cycle of a highly emetogenic regimen
             according to the MASCC criteria or the Hesketh criteria

          -  Patients with adequate metabolic or hematologic values for chemotherapy

          -  Patients with intact nasal mucosa

          -  Non child-bearing potential patients

          -  Patients able to read and write at a competent level, and capable of giving legal
             consent

          -  Patients who have provided written informed consent

        Exclusion Criteria:

          -  Patients who do not receive a chemotherapy regimen which is a highly emetogenic
             chemotherapy regimen according to the MASCC or the Hesketh criteria

          -  Patients with nasal cancers, pharyngeal cancers, maxillary sinus cancers, or ethmoid
             sinus cancers

          -  Patients with nasal ulcers, septal perforation, or other nasal conditions that may
             interfere with IN administration

          -  Patients with any episode of retching, vomiting, or uncontrolled nausea within 48
             hours before dosing with TRG and/or administration of chemotherapy

          -  Patients who have received radiation therapy in the 14 days before dosing with TRG, or
             for whom radiation therapy is scheduled during the 7 days after a TRG dose

          -  Patients who have received any investigational product within 30 days prior to study
             entry

          -  Patients who have received any drug or who were scheduled to receive any drug with
             antiemetic efficacy within 24 hours of the start of treatment

          -  Patients who have an allergy or hypersensitivity to granisetron or other selective
             5hydroxytryptamine3(5-HT3) receptor antagonists

          -  Patients with ECOG performance status of 3 or 4

          -  Patients who have or have a history of brain tumors, head cancers, or neck cancers

          -  Patients who have a psychological problem that, in the Investigator's opinion, is
             severe enough to interfere with study eligibility or with interpretation of study
             results

          -  Patients who are pregnant (urine test) or breastfeeding

          -  Patients who have received prior cytotoxic chemotherapy given for the treatment of
             cancer

          -  Patients scheduled to receive multiple day chemotherapy

          -  Patients with clinically relevant abnormal laboratory values at the discretion of the
             Investigator

          -  Patients with clinically relevant hepatic, renal, infectious, neurological, or
             psychiatric disorders, or any other major systemic illness at the discretion of the
             Investigator

          -  Patients with any prevalence or cause of nausea and vomiting other than chemotherapy

          -  Patients using systemic steroids for any indication, or patients using steroids other
             than dexamethasone for prevention of chemotherapy-induced nausea and vomiting, or
             patients using dexamethasone for chemotherapy-induced nausea and vomiting at doses
             other than recommended in the MASCC antiemetic guidelines

          -  Patients with a QT interval greater than 500 ms or with acute ischemic changes or
             cardiac abnormality predisposing to arrhythmia on screening electrocardiogram (ECG) or
             by history

          -  Patients with a history of drug and/or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The study is conducted at 14 Centers, in 14 cities accross the United States</name>
      <address>
        <city>The study is managed by Kendle International, in Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <results_first_submitted>May 24, 2011</results_first_submitted>
  <results_first_submitted_qc>May 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2011</results_first_posted>
  <last_update_submitted>July 5, 2011</last_update_submitted>
  <last_update_submitted_qc>July 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vanaja Ragavan, MD</name_title>
    <organization>Aviana Consulting, LLC</organization>
  </responsible_party>
  <keyword>Highly emetogenic chemotherapy induced nausea and vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.5 mg of TRG (Intranasal Granisetron)</title>
          <description>0.5 mg dose, intranasal powder, single spray, administered once</description>
        </group>
        <group group_id="P2">
          <title>1.0 mg of TRG (Intranasal Granisetron)</title>
          <description>1.0 mg dose, intranasal powder, single spray, administered once</description>
        </group>
        <group group_id="P3">
          <title>2.0 mg of TRG (Intranasal Granisetron)</title>
          <description>2.0 mg dose, intranasal powder, single spray, administered once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24">1 patient withdrew from the study due to an AE related to chemotherapy agent administration.</participants>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>AE related to chemotherapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5 mg of TRG (Intranasal Granisetron)</title>
          <description>0.5 mg dose, intranasal powder, single spray, administered once</description>
        </group>
        <group group_id="B2">
          <title>1.0 mg of TRG (Intranasal Granisetron)</title>
          <description>1.0 mg dose, intranasal powder, single spray, administered once</description>
        </group>
        <group group_id="B3">
          <title>2.0 mg of TRG (Intranasal Granisetron)</title>
          <description>2.0 mg dose, intranasal powder, single spray, administered once</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="15.9"/>
                    <measurement group_id="B2" value="60.0" spread="10.2"/>
                    <measurement group_id="B3" value="61.0" spread="12.0"/>
                    <measurement group_id="B4" value="58.9" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Complete Control</title>
        <description>Complete Control is defined as no emetic episodes, no use of rescue medications, and no more than mild nausea as defined by a categorial scale.</description>
        <time_frame>24 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg of TRG (Intranasal Granisetron)</title>
            <description>0.5 mg dose, intranasal powder, single spray, administered once</description>
          </group>
          <group group_id="O2">
            <title>1.0 mg of TRG (Intranasal Granisetron)</title>
            <description>1.0 mg dose, intranasal powder, single spray, administered once</description>
          </group>
          <group group_id="O3">
            <title>2.0 mg of TRG (Intranasal Granisetron)</title>
            <description>2.0 mg dose, intranasal powder, single spray, administered once</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Complete Control</title>
          <description>Complete Control is defined as no emetic episodes, no use of rescue medications, and no more than mild nausea as defined by a categorial scale.</description>
          <population>ITT population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="76.0"/>
                    <measurement group_id="O3" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Complete Response</title>
        <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Total Response</title>
        <description>Total Response is defined as no nausea, no emetic episodes, and no use of rescue medications</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Major Control of Emesis</title>
        <description>Major Control of emesis = 2 emetic episodes</description>
        <time_frame>24 hrs</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Minor Control of Emesis</title>
        <description>Minor Control of emesis: 3-5 emetic episodes</description>
        <time_frame>24 hrs</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Failure</title>
        <description>Failure: &gt; 5 emetic episodes</description>
        <time_frame>24 hrs</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Using Rescue Medications</title>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Emetic Episode</title>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Rescue Medication</title>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to treatment failure is based on time to first emetic episode or time to rescue medication, whichever occurs first</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Emetic Episodes</title>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nausea Measured by a 4 Categorical Scale</title>
        <description>4 categorical scale: none, mild (did not interfere with normal daily life), moderate (interfered with normal daily life), and severe (bedridden due to nausea/ required the patient to be bedridden)</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Satisfaction With Antiemetic Therapy Measured by a VAS</title>
        <description>VAS (visual analog scale) 0: not at all satisfied, 100: totally satisfied</description>
        <time_frame>24 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Dosing of study drug through safety follow-up period (maximum 38 days)</time_frame>
      <desc>Telephone questioning 2-24 hours after start of chemotherapy; 8 day patient diary</desc>
      <group_list>
        <group group_id="E1">
          <title>0.5 mg of TRG (Intranasal Granisetron)</title>
          <description>0.5 mg dose, intranasal powder, single spray, administered once</description>
        </group>
        <group group_id="E2">
          <title>1.0 mg of TRG (Intranasal Granisetron)</title>
          <description>1.0 mg dose, intranasal powder, single spray, administered once</description>
        </group>
        <group group_id="E3">
          <title>2.0 mg of TRG (Intranasal Granisetron)</title>
          <description>2.0 mg dose, intranasal powder, single spray, administered once</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <description>Not related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Not related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Not related to study medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Not related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Not related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Not related to study mediation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <description>Not related to study medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Not related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decrease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>SNBL and investigators agreed that SNBL would retain the exclusive right to disseminate data arising from the study through either publication or presentation, including study results, and that SNBL would retain exclusive editorial rights over manuscripts or presentations.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vanaja V. Ragavan, M.D.</name_or_title>
      <organization>Aviana Consulting, LLC</organization>
      <phone>610-795-7403</phone>
      <email>vvragavan@comcast.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

